NIH | National Cancer Institute | NCI Wiki  

You are viewing an old version of this page. View the current version.

Compare with Current View Page History

Version 1 Next »

Date

Attendees

Committee MemberPresentAbsent
Kuffel, Gina (NIH/NCI) [C]
X
Amy Leblanc

Otridge, John (NIH/NCI) [C]


X
Kim, Erika (NIH/NCI) [E]


Sommers, Connie (NIH/NCI) [E]



Debbie Knapp
X
Toby Hecht

Ralph Parchment

Goals

  • Discuss updates to ICDC and define emerging strategies and priorities

SharePoint Site

https://nih.sharepoint.com/sites/NCI-CBIIT-FNL-ICDC-ICDCLeadershipGroups

Outstanding Action Items

  • Debbie to write invitation for Jaime Modiano
  • Revisit new steering committee members in September 
  • Debbie Knapp to send an email to FidoCure and Vidium to see if these groups are willing to sit down and meet with us.

Agenda

ItemWhoTalking Points
Discussion of potential submission of FidoCure  Animal Health data

Sommers, Connie (NIH/NCI) [E] 

  • Create wish list of data to request from FidoCure
New article from Purdue Office of ResearchDebbie Knapp
DGAB Updates

Kuffel, Gina (NIH/NCI) [C] 

Recently Approved

  • COTC021
    • "Evaluation of Orally Administered mTOR inhibitor Rapamycin in Dogs in the Adjuvant Setting with Osteosarcoma"
    • 152 cases, 93 files
    • Full clinical dataset is available for both arms of this trial (324 dogs)
    • Scan H & E is available
    • Status: Approved by SAC on 6/30/23

ICDC Studies in Active Submission

  • ORGANOIDS01
    • Approved by SAC on 9/22/22
    • “Characterization of healthy and diseased canine tissues and organoids"
    • Iowa State University
    • Status: Data has been loaded to the Dev tier
BPSC Updates

Kuffel, Gina (NIH/NCI) [C] 

  • 2022 BPSC Review Article

    The manuscript entitled "Leading the Pack: Best Practices in Comparative Canine Cancer Genomics to Inform Human Oncology" has been accepted by the journal of Veterinary and Comparative Oncology. The ICDC will pay to ensure this article is open access.

Upcoming Steering Committee Meeting

Unknown User (parchmentr)

  • Enter date: Wednesday September 20th
2023 Q2 Software Release

Kuffel, Gina (NIH/NCI) [C] 

  • Released on August 15, 2023
  • New Features
    • JBrowse now supports text search so go ahead and find your favorite gene (Try it…Visit this page, select GLIOMA01 under the “Study” facet, and then click on the “Case Files” tab and select the first BAM file to “View in JBrowse”)
    • JBrowse has a new track that maps gene features from hg38 to canFam3
    • The Study, Study Details, and Program Details pages now feature interoperability between the ICDC, the Imaging Data Commons, and the Cancer Imaging Archive through the use of APIs to fetch details about imaging data hosted outside of the ICDC
    • Clinical observation data is now available for download on a node-by-node basis through a dedicated tab within the Study Details page
    • The Privacy Policy is now available within the footer of the Landing page
    • Updates to the ICDC News page
    • New README available within the “My Files” Cart page

Minutes (Not Verbatim)

AL - Jerry Post agreed that it is an exciting time for canine oncology. He thinks it would be a good idea for us to connect more. He expressed some concerns with integrating their data with our committee. They have novel data that would be interesting for the ICDC. Vidium has a publication out and may be more willing to share data.

TH - We should schedule a formal session with both groups to reconnect.

TH - Debbie has been in touch and has a paper that has been accepted that actually uses ICDC data.

TH - Cancer health disparity in acral melanoma in African Americans. Human dog comparative oncology could be important.

AL - Will H. has a paper that performs a broad assessment of canine melanomas in dogs

JO - Did we want to find out if there is publicly available data on this and bring it into the ICDC?

Previous ICDC Use Cases from Steering Committee

1. Genomic correlates across platforms (DNA, RNA, protein).

2. Correlating multi-omics data with clinical annotation and phenotypes, particularly outcomes.

3. Comparative analyses of canine and human. Examples include:

1. Search for conserved mutations between canine and human tumors

2. Disease diagnosis (e.g. cancer type) and classification mapping between canines and humans

5. Gene expression changes and mutational profiles associated with therapeutic response and outcome

6. How do sporadic tumors in non-human mammals compare to sporadic human tumors?

7. Correlations and model building from radiomic and pathomic features extracted from medical and histopathologic images with outcomes and genomics, as is currently being widely done with human images

8. Develop biomarkers of response and resistance in humans by analyzing the responses and genomic signatures in dogs.

Action items

  • No labels